Due to the high cost of genetic testing, the BCH uses stringent criteria for genetictesting indication, which can bring, as a side effect, the exclusion of at-riskfamilies, which is a serious issue, since patients with mutations identified in theBRCA1/BRCA2 genes, regardless of belonging to a small family, orbeing the only person affected by cancer in the family, have exactly the same risks forcancer development as patients from "high-risk families". Here, BRCA2 is linked to cancer.